In the ECLIPSE study, a head-to-head clinical trial comparing IL-23p19 blockade with guselkumab and IL-17A blockade with secukinumab for the treatment of moderate-to-severe psoriasis in adults (87). The gene discussed is IL23A; the disease is psoriasis.